{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:57:44Z","timestamp":1794121064463,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"50","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA259046"],"award-info":[{"award-number":["R01CA259046"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["21B04"],"award-info":[{"award-number":["21B04"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","award":["1068914"],"award-info":[{"award-number":["1068914"]}],"id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transcriptional dysregulation has emerged as a critical driver of melanoma progression, yet the molecular mechanisms governing this process and their potential as therapeutic targets remain inadequately characterized. Here, we identify FRA1 as a potent and actionable driver of melanoma metastasis. FRA1 enhanced both the initial seeding and subsequent outgrowth of metastatic lesions. Comprehensive multi-omics integration revealed transcriptional target genes of FRA1, with AXL, CDK6, and FSCN1 exhibiting increased expression in melanoma metastasis and a significant correlation with poor patient outcomes. Silencing AXL, CDK6, or FSCN1 abrogated FRA1-mediated invasion in vitro and reduced metastatic colonization. Furthermore, pharmacological inhibition of CDK6 and FSCN1, and to a lesser extent AXL, suppressed melanoma metastasis and prolonged overall survival. The expression of FRA1 and its target genes correlates with shortened survival across multiple cancer types, highlighting the broader clinical relevance of this pathway. This study unveils an actionable FRA1-mediated transcriptional network that drives cancer progression and metastasis, offering potential avenues for therapeutic interventions.<\/jats:p>","DOI":"10.1038\/s41388-025-03632-5","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:43:28Z","timestamp":1764017008000},"page":"4895-4909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FRA1 drives melanoma metastasis through an actionable transcriptional network"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-580X","authenticated-orcid":false,"given":"Xiaonan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinesh","family":"Jarajapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Chadourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulaida","family":"Soto-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-2355","authenticated-orcid":false,"given":"Shaaron L.","family":"Ochoa-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-5554","authenticated-orcid":false,"given":"Neel","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol","family":"Mecozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-9809","authenticated-orcid":false,"given":"Florian A.","family":"Karreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"3632_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3632_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502.","journal-title":"Lancet"},{"key":"3632_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.","journal-title":"Signal Transduct Target Ther"},{"key":"3632_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","volume":"48","author":"AV Pobbati","year":"2023","unstructured":"Pobbati AV, Kumar R, Rubin BP, Hong W. Therapeutic targeting of TEAD transcription factors in cancer. Trends Biochem Sci. 2023;48:450\u201362.","journal-title":"Trends Biochem Sci"},{"key":"3632_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/0008-5472.CAN-23-1730","volume":"84","author":"X Xu","year":"2024","unstructured":"Xu X, Bok I, Jasani N, Wang K, Chadourne M, Mecozzi N, et al. PTEN lipid phosphatase activity suppresses melanoma formation by opposing an AKT\/mTOR\/FRA1 signaling axis. Cancer Res. 2024;84:388\u2013404.","journal-title":"Cancer Res"},{"key":"3632_CR6","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/s41388-020-1306-4","volume":"39","author":"F Talotta","year":"2020","unstructured":"Talotta F, Casalino L, Verde P. The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications\u2019 door. Oncogene. 2020;39:4491\u2013506.","journal-title":"Oncogene"},{"key":"3632_CR7","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/onc.2017.135","volume":"36","author":"K Maurus","year":"2017","unstructured":"Maurus K, Hufnagel A, Geiger F, Graf S, Berking C, Heinemann A, et al. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene. 2017;36:5110\u201321.","journal-title":"Oncogene"},{"key":"3632_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100076","volume":"2","author":"I Bok","year":"2022","unstructured":"Bok I, Angarita A, Douglass SM, Weeraratna AT, Karreth FA. A series of BRAF- and NRAS-driven murine melanoma cell lines with inducible gene modulation capabilities. JID Innov. 2022;2:100076.","journal-title":"JID Innov"},{"key":"3632_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/0008-5472.CAN-19-2924","volume":"80","author":"I Bok","year":"2020","unstructured":"Bok I, Vera O, Xu X, Jasani N, Nakamura K, Reff J, et al. A versatile ES cell-based melanoma mouse modeling platform. Cancer Res. 2020;80:912\u201321.","journal-title":"Cancer Res"},{"key":"3632_CR10","doi-asserted-by":"publisher","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","volume":"12","author":"B Bushnell","year":"2017","unstructured":"Bushnell B, Rood J, Singer E. BBMerge\u2014accurate paired shotgun read merging via overlap. PLoS One. 2017;12:e0185056.","journal-title":"PLoS One"},{"key":"3632_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1089\/cmb.2017.0096","volume":"24","author":"A Kechin","year":"2017","unstructured":"Kechin A, Boyarskikh U, Kel A, Filipenko M. cutPrimers: a new tool for accurate cutting of primers from reads of targeted next generation sequencing. J Comput Biol. 2017;24:1138\u201343.","journal-title":"J Comput Biol"},{"key":"3632_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3632_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.","journal-title":"BMC Bioinforma"},{"key":"3632_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3632_CR15","doi-asserted-by":"publisher","first-page":"e21856","DOI":"10.7554\/eLife.21856","volume":"6","author":"PJ Skene","year":"2017","unstructured":"Skene PJ, Henikoff S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. Elife. 2017;6:e21856.","journal-title":"Elife"},{"key":"3632_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139.","journal-title":"Nat Methods"},{"key":"3632_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.585","volume":"2","author":"Q Wang","year":"2022","unstructured":"Wang Q, Li M, Wu T, Zhan L, Li L, Chen M, et al. Exploring epigenomic datasets by ChIPseeker. Curr Protoc. 2022;2:e585.","journal-title":"Curr Protoc"},{"key":"3632_CR18","doi-asserted-by":"publisher","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","volume":"9","author":"M Lawrence","year":"2013","unstructured":"Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, et al. Software for computing and annotating genomic ranges. PLoS Comput Biol. 2013;9:e1003118.","journal-title":"PLoS Comput Biol"},{"key":"3632_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66998-4","volume":"10","author":"P Gontarz","year":"2020","unstructured":"Gontarz P, Fu S, Xing X, Liu S, Miao B, Bazylianska V, et al. Comparison of differential accessibility analysis strategies for ATAC-seq data. Sci Rep. 2020;10:10150.","journal-title":"Sci Rep"},{"key":"3632_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3632_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"3632_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"3632_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25:59\u201373.","journal-title":"Nat Rev Cancer"},{"key":"3632_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3632_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Consortium ITP-CAoWG.","year":"2020","unstructured":"Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578:82\u201393.","journal-title":"Nature"},{"key":"3632_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.tcb.2013.06.001","volume":"23","author":"B Ell","year":"2013","unstructured":"Ell B, Kang Y. Transcriptional control of cancer metastasis. Trends Cell Biol. 2013;23:603\u201311.","journal-title":"Trends Cell Biol"},{"key":"3632_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0082-2","volume":"7","author":"J Grimm","year":"2018","unstructured":"Grimm J, Hufnagel A, Wobser M, Borst A, Haferkamp S, Houben R, et al. BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1. Oncogenesis. 2018;7:71.","journal-title":"Oncogenesis"},{"key":"3632_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature24037","volume":"550","author":"X Kong","year":"2017","unstructured":"Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550:270\u20134.","journal-title":"Nature"},{"key":"3632_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, et al. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2018;8:74\u201393.","journal-title":"Cancer Discov"},{"key":"3632_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368\u201372.","journal-title":"Nature"},{"key":"3632_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111147","volume":"40","author":"N Comandante-Lou","year":"2022","unstructured":"Comandante-Lou N, Baumann DG, Fallahi-Sichani M. AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells. Cell Rep. 2022;40:111147.","journal-title":"Cell Rep"},{"key":"3632_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature. 2022;610:190\u20138.","journal-title":"Nature"},{"key":"3632_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/cancers14061480","volume":"14","author":"L Casalino","year":"2022","unstructured":"Casalino L, Talotta F, Cimmino A, Verde P. The Fra-1\/AP-1 oncoprotein: from the \u201cundruggable\u201d transcription factor to therapeutic targeting. Cancers. 2022;14:1480.","journal-title":"Cancers"},{"key":"3632_CR34","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.3390\/ijms24098307","volume":"24","author":"L Casalino","year":"2023","unstructured":"Casalino L, Talotta F, Matino I, Verde P. FRA-1 as a regulator of EMT and metastasis in breast cancer. Int J Mol Sci. 2023;24:8307.","journal-title":"Int J Mol Sci"},{"key":"3632_CR35","doi-asserted-by":"publisher","first-page":"39996","DOI":"10.18632\/oncotarget.9557","volume":"7","author":"RL Hanson","year":"2016","unstructured":"Hanson RL, Brown RB, Steele MM, Grandgenett PM, Grunkemeyer JA, Hollingsworth MA. Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget. 2016;7:39996\u201340011.","journal-title":"Oncotarget"},{"key":"3632_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109443","volume":"36","author":"C Dai","year":"2021","unstructured":"Dai C, Rennhack JP, Arnoff TE, Thaker M, Younger ST, Doench JG, et al. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Rep. 2021;36:109443.","journal-title":"Cell Rep"},{"key":"3632_CR37","doi-asserted-by":"publisher","first-page":"43146","DOI":"10.18632\/oncotarget.6454","volume":"6","author":"S Iskit","year":"2015","unstructured":"Iskit S, Schlicker A, Wessels L, Peeper DS. Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival. Oncotarget. 2015;6:43146\u201361.","journal-title":"Oncotarget"},{"key":"3632_CR38","doi-asserted-by":"publisher","first-page":"e88950","DOI":"10.1371\/journal.pone.0088950","volume":"9","author":"J Diesch","year":"2014","unstructured":"Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, et al. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One. 2014;9:e88950.","journal-title":"PLoS One"},{"key":"3632_CR39","doi-asserted-by":"publisher","first-page":"34371","DOI":"10.18632\/oncotarget.9110","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Wu J, Luo S, Lechler T, Zhang JY. FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms. Oncotarget. 2016;7:34371\u201383.","journal-title":"Oncotarget"},{"key":"3632_CR40","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/0008-5472.CAN-06-4687","volume":"67","author":"P Adiseshaiah","year":"2007","unstructured":"Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res. 2007;67:6204\u201311.","journal-title":"Cancer Res"},{"key":"3632_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","volume":"24","author":"J Caramel","year":"2013","unstructured":"Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24:466\u201380.","journal-title":"Cancer Cell"},{"key":"3632_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun"},{"key":"3632_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"3632_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18:153.","journal-title":"Mol Cancer"},{"key":"3632_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","volume":"24","author":"K Kollmann","year":"2013","unstructured":"Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24:167\u201381.","journal-title":"Cancer Cell"},{"key":"3632_CR46","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/nature08978","volume":"464","author":"L Chen","year":"2010","unstructured":"Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY. Migrastatin analogues target fascin to block tumour metastasis. Nature. 2010;464:1062\u20136.","journal-title":"Nature"},{"key":"3632_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41388-021-02142-4","volume":"41","author":"L Shu","year":"2022","unstructured":"Shu L, Chen A, Li L, Yao L, He Y, Xu J, et al. NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1\/2-mediated Fbxw7 phosphorylation. Oncogene. 2022;41:907\u201319.","journal-title":"Oncogene"},{"key":"3632_CR48","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1038\/s41388-019-0763-0","volume":"38","author":"T Wang","year":"2019","unstructured":"Wang T, Song P, Zhong T, Wang X, Xiang X, Liu Q, et al. The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties. Oncogene. 2019;38:4932\u201347.","journal-title":"Oncogene"},{"key":"3632_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108948","volume":"35","author":"Y Wang","year":"2021","unstructured":"Wang Y, Song M, Liu M, Zhang G, Zhang X, Li MO, et al. Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. Cell Rep. 2021;35:108948.","journal-title":"Cell Rep"},{"key":"3632_CR50","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.celrep.2015.12.104","volume":"14","author":"X Liu","year":"2016","unstructured":"Liu X, Li H, Rajurkar M, Li Q, Cotton JL, Ou J, et al. Tead and AP1 coordinate transcription and motility. Cell Rep. 2016;14:1169\u201380.","journal-title":"Cell Rep"},{"key":"3632_CR51","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","volume":"37","author":"Q Zuo","year":"2018","unstructured":"Zuo Q, Liu J, Huang L, Qin Y, Hawley T, Seo C, et al. AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene. 2018;37:3275\u201389.","journal-title":"Oncogene"},{"key":"3632_CR52","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/bjc.2014.453","volume":"111","author":"H Ghebeh","year":"2014","unstructured":"Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, et al. Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K\/Akt pathway. Br J Cancer. 2014;111:1552\u201361.","journal-title":"Br J Cancer"},{"key":"3632_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41420-021-00778-5","volume":"7","author":"J Pu","year":"2021","unstructured":"Pu J, Huang Y, Fang Q, Wang J, Li W, Xu Z, et al. Hypoxia-induced Fascin-1 upregulation is regulated by Akt\/Rac1 axis and enhances malignant properties of liver cancer cells via mediating actin cytoskeleton rearrangement and Hippo\/YAP activation. Cell Death Discov. 2021;7:385.","journal-title":"Cell Death Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03632-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T23:03:16Z","timestamp":1764630196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03632-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":53,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025,12,23]]}},"alternative-id":["3632"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03632-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All procedures involving animals were approved by the Institutional Animal Care and Use Committee (IACUC, protocol number: 12845\u2009R) and conducted in accordance with institutional and national guidelines. No human identifiable images are included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}